CTA
TPTX

Carillon Tower Advisers’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Carillon Tower Advisers’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$32.9M Sell
269,743
-28,912
-10% -$3.17M 0.2% 153
2020
Q3 		$26.1M Buy
298,655
+15,293
+5% +$1.07M 0.35% 91
2020
Q2 		$18.3M Buy
+283,362
New +$16.3M 0.14% 209

Other funds holding TPTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Carillon Tower Advisers's TPTX Position: Q4 2020 in Review

Carillon Tower Advisers reduced its Turning Point Therapeutics, Inc. Common Stock (TPTX) stake by 9.7% in Q4 2020, selling an estimated $3.17M and leaving 269,743 shares worth $32.9M. The position accounts for 0.2% of the portfolio, ranked #153.

Carillon Tower Advisers first reported a position in TPTX in Q2 2020 and has held it in 3 quarters since. 193 funds tracked by Wall St. Rank hold TPTX as of Q4 2020.

  • Carillon Tower Advisers held 269,743 shares of Turning Point Therapeutics, Inc. Common Stock worth $32.9M as of Q4 2020.
  • Carillon Tower Advisers sold 28,912 Turning Point Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $3.17M.
  • Turning Point Therapeutics, Inc. Common Stock made up 0.2% of Carillon Tower Advisers's portfolio in Q4 2020, its #153 holding.
  • Carillon Tower Advisers first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2020 and has held it in 3 quarters since.
  • 193 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.